-
Min Investment
-
$300
-
Location
-
San Antonio , TX
-
Expected Close Date
-
September 03, 2024
-
Target Raise
-
$15.00K-$3.00M
-
Security Price
-
$3
- Number of Employees
- 9
- Cash
- $111,047
- Revenue
- $550,450
- Short Term Debt
- $1,586,281
- Cost of Goods
- $0
- Long Term Debt
- $405,497
- Net Income
- $-1,537,261
Company Description
StemBioSys® is a biomedical company whose advanced cell technologies can test drugs more efficiently and accurately without using animal models.
Key Deal Facts
StemBioSys® innovates drug testing with patented lab tools allowing the testing of new products with cultured human cells, not from embryos, replacing less accurate chemical tests & experimental animal models.
StemBioSys® has established a strong foothold in the biopharmaceutical, academic, and government markets with pioneering products such as CELLvo™ Atrial Cardiomyocytes and our patented Matrix Plus™.